title: [Prophylaxis and treatment of adynamic bone].
abstract: The pathogenesis of adynamic bone disease (ABD) attributes to calcium overload, active vitamin D (VD) metabolism, increase in inactive PTH (parathyroid hormone) fragments, or derangement of bone metabolism regulation factors. In particular, increased Ca overload plays a critical role in the development of ABD. Thus, alleviated Ca load by sevelamer hydrochloride and appropriate VD administration could be effective on not only prevention, and also treatment of ABD.
authors.affiliation: Internal Medicine, Showa University Northern Yokohama Hospital.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ogata
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Susumu
authors.initials: S
authors.lastname: Taguchi
mesh_terms: D000818:Animals; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000502:physiology; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D002352:Carrier Proteins / Q000502:physiology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology* / Q000517:prevention & control* / Q000628:therapy; D000069449:Cinacalcet; D004852:Epoxy Compounds / Q000627:therapeutic use*; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D008562:Membrane Glycoproteins / Q000502:physiology; D009281:Naphthalenes / Q000627:therapeutic use; D053244:Osteoprotegerin; D010281:Parathyroid Hormone / Q000378:metabolism / Q000502:physiology; D011073:Polyamines; D011095:Polyethylenes / Q000627:therapeutic use*; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018167:Receptors, Calcitriol / Q000502:physiology; D044169:Receptors, Calcium-Sensing / Q000819:agonists / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor; D012306:Risk; D000069603:Sevelamer; D016212:Transforming Growth Factor beta / Q000502:physiology; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D004852:Epoxy Compounds; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D009281:Naphthalenes; D053244:Osteoprotegerin; D010281:Parathyroid Hormone; D011073:Polyamines; D011095:Polyethylenes; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018167:Receptors, Calcitriol; D044169:Receptors, Calcium-Sensing; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D016212:Transforming Growth Factor beta; D014807:Vitamin D; D000069603:Sevelamer; D002118:Calcium; D000069449:Cinacalcet